Clinicopathological characteristics and outcome of 31 patients with ETV6-NTRK3 fusion gene confirmed (mammary analogue) secretory carcinoma of salivary glands

•We evaluated 31 patients with secretory carcinoma of salivary glands.•Clinical outcomes were generally good with 5- and 10-year overall survival of 95%.•One patient developed a local recurrence, no regional or distant recurrences.•Elective neck treatment does not seem indicated given the excellent...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oral oncology 2018-07, Vol.82, p.29-33
Hauptverfasser: Boon, E., Valstar, M.H., van der Graaf, W.T.A., Bloemena, E., Willems, S.M., Meeuwis, C.A., Slootweg, P.J., Smit, L.A., Merkx, M.A.W., Takes, R.P., Kaanders, J.H.A.M., Groenen, P.J.T.A., Flucke, U.E., van Herpen, C.M.L.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•We evaluated 31 patients with secretory carcinoma of salivary glands.•Clinical outcomes were generally good with 5- and 10-year overall survival of 95%.•One patient developed a local recurrence, no regional or distant recurrences.•Elective neck treatment does not seem indicated given the excellent outcomes. In 2010, a new subtype of salivary gland cancer (SGC), (mammary analogue) secretory carcinoma (SC), was defined, characterized by the ETV6-NTRK3 fusion gene. As clinical behavior and outcome data of this histological subtype tumor are still sparse, we aimed to describe the clinicopathological course and outcome of a series of translocation positive SC patients. We re-evaluated the pathological diagnosis of a subset of SGCs, diagnosed in 4 of 8 Dutch head and neck centers. Subsequently, tumors with a morphological resemblance to SC were tested for the ETV6-NTRK3 fusion gene using RT-PCR. Furthermore, patients prospectively diagnosed with SC were included. The clinical characteristics and outcomes were retrieved from the patient files. Thirty-one patients with ETV6-NTRK3 fusion gene positive SC were included. The median age was 49 years, 17 patients (55%) were male. Eighteen tumors (58%) arose in the parotid gland. One patient presented with lymph node metastasis. All patients underwent tumor resection and 4 patients had a neck dissection. Four patients had re-resection and 15 patients (48%) received postoperative radiotherapy. One patient developed a local recurrence, no regional recurrences or distant metastases were observed. After a median follow-up of 49 months the 5- and 10-year overall survival were 95%, the 5- and 10-year disease free survival were 89%. The clinical course of SC is favorable with a low rate of locoregional recurrence and excellent survival. Given the low incidence of nodal metastases, elective neck treatment, i.e. surgery and/or radiotherapy, does not seem to be indicated.
ISSN:1368-8375
1879-0593
DOI:10.1016/j.oraloncology.2018.04.022